Navigation Links
Study offers window into human behavior, brain disease

UCSF scientists have identified a cell population that is a primary target of the degenerative brain disease known as frontotemporal dementia, which is as common as Alzheimer's disease in patients who develop dementia before age 65.

Because the cells arose only recently in evolutionary history -- in a common ancestor of great apes and humans-- and are particularly abundant in humans, and the finding supports the concept that evolution has rendered the human brain vulnerable to disease, including frontotemporal dementia, and, possibly, disorders such as autism and schizophrenia, the researchers say.

In addition, because the disease erodes aspects of social behavior and emotions ?self awareness, moral reasoning and empathy ?that are highly developed in humans, the finding suggests that the cells may play a role in what makes humans "human," they say.

The finding is reported in the December 22 on-line issue of Annals of Neurology.

The cells, known as von Economo neurons, were first comprehensively described in 1925 by their Romanian-Austrian namesake, who determined that the unusually shaped cells -- large, cigar-shaped and tapered at each end, with only a few dendritic processes extending away from them ?were localized in only two regions of the frontal lobes.

The cells received only limited attention in the ensuing years, but in the meantime scientists determined that the brain regions in which von Economo neurons arise -- the anterior cingulate and frontoinsular cortex -- are key targets of frontotemporal dementia. And in 1999, a team of U.S. scientists made the surprising discovery that, among primates, von Economo neurons were seen only in great apes and humans.

In the current study, the UCSF team set out to explore whether von Economo neurons could be the target of FTD.

Working in the laboratory of senior author Stephen J. DeArmond, MD, PhD, UCSF professor of pathology, they compared the numbers of von Economo neurons and neighboring neurons in the anterior cingulate cortex, looking specifically at brain tissue from three sets of deceased patients -- seven who had no neurological disease, five who had Alzheimer's disease and seven who had frontotemporal dementia.

The results were striking. In frontotemporal dementia, there was early, severe and selective loss of von Economo neurons compared to control subjects. In Alzheimer's disease, von Economo neurons were not significantly depleted.

"This finding provides new insight into how frontotemporal dementia erodes the brain at the cellular level," says the first author of the study, William Seeley, MD, UCSF instructor of neurology and a clinician-scientist at the UCSF Memory and Aging Center.

Progress has been made in illuminating some of the genetic and molecular aspects of the disease ?two mutated genes are associated with most inherited forms of the disease and major misprocessed proteins have been identified ?but "discoveries at the genetic and molecular level do not yet explain why specific populations of neurons are dying," he says.

"This observation gives us a new window into the early and cell-specific degenerative process, and we can use this window to better understand disease pathogenesis."

The team, led by Seeley, is currently trying to study von Economo neuron-rich regions in living patients using neuroimaging. They also are studying VENs, themselves, in autopsy studies using neuropathological techniques.

As FTD is a disease for which there is as yet no disease-modifying therapy, studies of von Economo neurons could provide new strategies.

Why the cells are vulnerable is still a mystery, says Seeley. But given the fact that they are evolutionarily new, the explanation may be that there are still "kinks" in the genetic programming of the neuronal circuits.

"VENs probably help us in some wonderful way, which would explai n why natural selection has pushed their rapid evolution in humans," he says. "Still, in the context of FTD, something about VENs makes them vulnerable."

Notably, cell-specific degeneration is a unifying feature of all the neurodegenerative diseases. Dopamine-producing neurons in the substantia nigra region of the brain deteriorate in Parkinson's disease, motor neurons of the spinal cord and motor cortex degenerate in ALS and specific memory-forming medial temporal lobe neurons die in early Alzheimer's disease.

"We hope to add von Economo neurons to that list," says Seeley. "It's a pretty important list to fill in, but for FTD there just hasn't been a good candidate until now. We think we've found it, and that is the most exciting part of the discovery for those of us who treat patients."

At the same time, he says, the finding "gives us a sense that we might be able to start to figure out what makes us unique as humans, what makes our brains different from those of other species. And that's pretty exciting, too."

Bruce Miller, MD, the A.W. & Mary Margaret Clausen Distinguished Professor of Neurology, director of the UCSF Memory and Aging Center and a co-author of the study, concurs.

"The social and behavioral skills that you lose in frontotemporal dementia are so characteristically human, or at least strongly associated with higher primates," he reflects.

"I think it's fascinating from an evolutionary perspective that we have these new neurons that are involved in social behavior that are selectively vulnerable in the second major degenerative disorder."

Notably, VENs are located in regions of the brain that are in a good position to transmit raw emotional signals to other brain centers. In addition, VENs have characteristics that suggest they play a role in analyzing sparse inputs and sending rapid output signals, further supporting the idea that they may impact behavior.

It's possible, says Seeley, that scientists will be able to figure out what these neurons normally do. But it won't be easy.

"These are such abstract brain capacities we're talking about…It's not like analyzing movement of your right arm or color vision. We're talking about understanding how we read others' minds. The philosopher in me sees the opportunity to really learn something interesting about human nature, here."

Still, he says, "It's the neurologist in me that brings me to work everyday, and as a neurologist what I want is to help cure the disease."


'"/>

Source:University of California - San Francisco


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... Research and Markets has announced the addition ... to their offering. ... The global voice recognition biometrics market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):
(Date:2/15/2017)... 2017  Trianni, Inc. („TRIANNI") gab heute bekannt, ... Lizenzvereinbarung über die Verwendung der The Trianni Mouse ... die Entdeckung monoklonaler Antikörper. Die Trianni ... aus, das Janssen den Zugang zu ... das für die schelle Isolierung vollständig menschlicher Therapeutika ...
(Date:2/15/2017)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced ... and full year ended December 31, 2016. ... as we continued to demonstrate strong growth in ... Fanapt," said Mihael H. Polymeropoulos, M.D., Vanda,s President ... important 2017 milestones underscores Vanda,s commitment to bringing ...
(Date:2/15/2017)... Feb. 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, will ... presentation) at 8:00 AM EST on Thursday, February 16, ... clinical program, the recently announced closing of a $10.5 ... To participate in the live call and ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health (Diameter) ... Health technology in the hands of Lantana analysts. The high-performance platform of Diameter ... public health entities – all those mining value from clinical data – to ...
Breaking Biology Technology: